



General Section Original Article 




Dept. of Pediatrics, Patan 







Prof. Dr. Nabees Pradhan, 
Patan Academy of Health 
Sciences, Nepal 
 
Asst. Prof. Dr. Sumana 
Bajracharya,  Patan Academy of 




28 Oct 2021 
 
Accepted 
20 Nov 2021 
 
 
How to cite this article  
Sucharita Tuladhar, Puja 
Amatya, Rateena Rajbhandari, 
Anu Maharjan, Anil Raj Ojha, 
Ganesh Shah. Clinical profile 
and outcome of COVID-19 in 
pediatric hematology-oncology 
patients. Journal of Patan 






Clinical profile and outcome of COVID-19 in 
pediatric hematology-oncology patients 
Sucharita Tuladhar1 , Puja Amatya2  , Rateena Rajbhandari2 , Anu 
Maharjan3 , Anil Raj Ojha4 , Ganesh Shah5  
 
1Lecturer, 2Asst. Prof., 4Assoc. Prof., 5Prof., Dept. of Pediatrics, 3Lecturer, Dept. of 





Introduction: Pediatric hematology-oncology patients are assumed to be 
predisposed to severe COVID-19 disease and complications, but robust 
data from low- and middle-income countries is lacking. This study was 
designed with the primary objective of finding the prevalence and 
outcome of COVID- 19 in children with hematological or oncological 
diseases. Clinical characteristics of COVID-19, outcomes in terms of need 
for respiratory support, intensive care, mechanical ventilation or 
mortality, delay in therapy, and use of COVID-19 directed therapy were 
analyzed. 
 Method: Retrospective review of all children with hematological or 
oncological diseases with confirmed COVID-19 managed at Patan 
Hospital from Jan 2020 to Sep 2021. Patients were screened according to 
the hospital screening protocol. The clinical characteristics and outcomes 
of COVID-19 along with the delay in chemotherapy or local therapy were 
recorded. 
 Result: Twelve children tested positive for SARS- CoV-2 during the study 
period, and one had reinfection with COVID-19, 9(75%) were oncology 
patients, while 3(25%) were hematology patients. Fever (83.3%) was the 
most common symptom, followed by cough (58.3%). Four (33.3%) 
children had mild infections, and 4(33.3%) had severe infections. Eight 
oncology patients had delays in starting or continuing chemotherapy or 
undergoing surgery due to COVID-19. The median duration of delay was 
10.5 d (range-7-21 d). The delay in therapy in patients with COVID-19 was 
significant in comparison to children without COVID-19. 
 Conclusion: The majority of pediatric hematology-oncology patients 
recovered from COVID-19 without sequelae. There was a delay in 
providing treatment to oncology patients due to changing protocols. 
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Introduction 
 
Coronavirus disease 2019 (COVID-19) caused 
by novel severe acute respiratory syndrome 
Coronavirus-2 (SARS-CoV-2) has created havoc 
all over the world.1 Most countries are 
struggling to control the spread of virus and 
healthcare systems are struggling to stay 
afloat.2 The brunt of infection has been taken 
by the elderly and people with co-morbidities.1 
Studies show immunocompromised adults 
succumbed more to COVID-19 in comparison 
to the healthy population.3 Children remain 
comparatively safer age group, but the same 
might not hold for immunocompromised 
children as comprehensive data is not 
available.1,4,5 The dilemma for pediatric 
oncologists is whether to go ahead with 
intensive immunosuppressive therapy versus 
low dose bridging therapy or withhold therapy 
given the ongoing pandemic. Challenge 
remains as recent reviews show higher 
mortality and increased severity of disease in 
pediatric oncology patients4 in contrast to 
previous studies showing risk at par to normal 
children.6,7 
 
Data regarding the prevalence and outcome of 
COVID-19 in children with malignancies is 
scarce. A retrospective study from the USA 
revealed higher morbidity and mortality in 
pediatric oncology patients than normal 
children1 whereas an Indian study revealed 
that 7% of patients required respiratory 
support.8 The status of this group of children in 
Nepal is under-reported, thus this study will 
help in further management of this cohort of 
children. As the pediatric hematology-
oncology services at Patan Hospital, Patan 
Academy of Health Sciences (PAHS) was 
started 2 y ago, this study aimed to describe 
the clinical characteristics, natural history, and 
outcome of COVID-19 in children with 




This is a retrospective chart review of all the 
children with underlying hematological or 
oncological diseases with COVID-19 confirmed 
by RT-PCR or COVID antigen detection test 
managed at Patan Hospital, Patan Academy of 
Health Sciences (PAHS) from January 2020 till 
September 2021. Ethical approval was 
obtained from the Institutional Review 
Committee of PAHS following which data 
collection was done. Patient information was 
extracted from medical records and electronic 
data using hospital numbers. Patients with 
incomplete data were excluded from the 
study. The data were deidentified to ensure 
strict anonymity. For COVID-19 positive 
patients, data on demographics, clinical 
symptoms, the severity of COVID-196(Table 1), 
investigations, imaging, hospital course, stage 
of cancer-related therapy, the severity of 
chemotherapy1(Table 2), and impact of COVID-
19 on the therapy were extracted from 
records. 
 
As per the protocol, on presentation to the 
hospital for inpatient or outpatient care, 
children were screened for the presence of 
COVID-19 related symptoms or exposure to 
contacts with SARS-CoV-2 infection. The 
screening criteria for COVID-19 was based on 
the hospital protocol which was revised thrice 
during the study period in September 2020, 
October 2020, and June 2021 respectively.  
Children with fever and respiratory symptoms 
were tested for SARS-CoV-2 infection in their 
nasopharyngeal and oropharyngeal swabs 
using reverse transcriptase-polymerase chain 
reaction (RT-PCR) test while with fever with 
gastrointestinal or any other symptoms related 
to COVID-19 without respiratory symptoms 
were tested with either COVID antigen 
detection or RT-PCR test. The RT-PCR test was 
also instituted in asymptomatic children 
before elective surgery, radiation, deep 
sedation for invasive procedures, or each cycle 
of myelosuppressive chemotherapy. The 
elective surgery was withheld in children who 
tested positive till RT-PCR for COVID-19 was 
negative and the patient was clinically stable.  
The decision to start or continue 
myelosuppressive chemotherapy was based 
on the clinical status of the patient and the 
urgency of treatment. 
All hematology patients with fever and 
respiratory distress were admitted and treated 
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were continued till the child was afebrile for at 
least 24 h and blood culture at 72 h of 
inoculation was sterile. All oncology patients 
with fever and neutropenia (Absolute 
neutrophil count<500/mm3) were admitted 
and treated with empirical intravenous 
antibiotics after sending blood culture 
irrespective of the RT-PCR report. The 
antibiotics were continued till blood culture at 
72 h of inoculation is sterile and the patient 
was afebrile for at least 24-48 h. Antibiotics 
were started depending upon the 
departmental protocol for febrile neutropenia 
patients. Oncology patients on mild 
chemotherapy with fever and without 
neutropenia and respiratory distress and 
symptomatic patients were managed at home 
with intermittent review by the treating 
physician over the phone.  
 
Descriptive analysis was performed using 
Microsoft Excel. Categorical data are 
presented with frequency and percentage. The 
sub-group analysis to find the association 
between the delay in chemotherapy or surgery 
in oncological patients with COVID-19 was 
performed using the Chi-square test. p-value 
0.05 was considered statistically significant. 
All patient identifiers were replaced in the 
study by case identification numbers to protect 





There was a total of 35 patients under the age 
of 14 y with various hematological and 
oncological diseases managed at Patan 
Hospital, PAHS till September 2021 out of 
which 27 had various malignancies. Among 
them, 12 tested positive for SARS-CoV-2 during 
the study period and one child with Acute 
Lymphoblastic Leukemia (ALL) had reinfection 
with COVID-19 after a period of 9 mo. Among 
children with various malignancies and COVID-
19, 4(33.3%) had acute leukemia making it the 
most common diagnosis. Among children with 
non-malignant diseases 1(8%) had hemophilia 
and 2(16%) had iron deficiency anemia. For 
symptomatic infection, 9(75%) patients were 
admitted for treatment whereas one patient 
with mild disease and two asymptomatic 
patients were managed at home under the 
physician’s guidance. 
 
All were symptomatic except for 2(16.7%) 
patients. Both asymptomatic patients tested 
positive on screening before surgery. Three 
patients were diagnosed with COVID-19 at the 
time of diagnosis of malignancy. Out of these, 
two patients were symptomatic with fever, 
headache, body ache without respiratory 
symptoms and both underwent bone marrow 
aspiration and biopsy under intravenous 
sedation with ketamine and midazolam for 
confirmation and categorization of leukemia 
while suffering from COVID-19. 
 
Only 1(8.3%) patient had a critical illness and 
he was neutropenic as well as lymphopenic at 
the time of diagnosis of COVID-19. Mild and 
severe diseases accounted for 4(33.3%) 
patients each while 1(8.3%) had moderate 
disease, Figure 1. The patient with reinfection 
with COVID-19 had a mild disease in both 
episodes. He was admitted and given empirical 
antibiotics during the first episode as he was 
receiving severe myelosuppressive 
chemotherapy and was neutropenic. The 
chemotherapy was withheld during this 
period. During reinfection, he was receiving 
mild myelosuppressive chemotherapy and was 
non-neutropenic thus he was managed at 
home, and chemotherapy was continued 
throughout the period and was not started on 
empirical antibiotics. There were 4(33.3%) 
neutropenic and lymphopenic patients at the 
time of diagnosis of SARS-CoV-2 infection. Out 
of the four patients with neutropenia and 
lymphopenia, one had critical illness while two 
had mild disease and one had a moderate 
disease. Out of four patients with severe 
disease, one was an oncology patient while 
three were hematology patients. The patient 
with critical COVID-19 disease who was 
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at presentation died within 4 h of hospital 
admission. The remaining patients recovered 
from COVID-19 without sequelae. One patient 
with hemophilia developed intracranial 
bleeding while suffering from COVID-19 and 
had to be transferred to another center with a 
neurosurgical facility. One patient died due to 
progressive malignancy after recovery from 
COVID-19. The data regarding the duration of 
negative RT-PCR reports were available in 
7(58.3%) patients. The duration was 4 w in 
1(14%) patient, 3 w in 2(28.5%) patients and 2 
w in 4(57%) patients. 
 
Out of nine oncology patients, 2(22.2%) were 
receiving severe, 3(33.3%) moderate, and 
1(11.1%) mild intensity chemotherapy; 
1(11.1%) was receiving targeted therapy and 
3(33.3%) patients were RT-PCR positive for 
SARS-CoV-2 at the time of diagnosis. Among 
three patients who were diagnosed with 
COVID-19 at the time of diagnosis of 
malignancy, two patients received cancer-
directed therapy after testing negative for 
COVID-19, while one was started on 
chemotherapy despite a positive COVID-19 
report. The patient with COVID-19 at the 
diagnosis of ALL was started on steroids as a 
part of chemotherapy rather than as COVID-19 
directed therapy. The patient was persistently 
febrile without respiratory symptoms at the 
time of starting steroids. None of the children 
with hematological or oncological diseases 
received COVID-19 directed therapy like 
steroids, remdesevir or tocilizumab, or 
plasmapheresis. 
 
Out of nine oncology patients with positive 
COVID-19 reports, 8(88.9%) had a delay in 
starting or continuing chemotherapy or 
undergoing surgery, which was statistically 
significant (p value<0.01), Table 5. The median 
duration of delay in therapy was 10.5 d (range 
7-21 d). Two leukemia patients receiving mild 
intensity chemotherapy continued 
chemotherapeutic drugs while suffering from 
COVID-19. Both the patients with mild and 
moderate diseases recovered without 
sequelae. 
 1 
Table 1. Coronavirus severity index6 2 
 3 
 4 
Asymptomatic Asymptomatic but positive diagnostic test (undertaken for other reasons). 
Mild Symptoms of acute upper respiratory tract infection, including fever, fatigue, myalgia, 
cough, sore throat, runny nose, and sneezing. Clear chest on auscultation. Some cases may 
have no fever or have only digestive symptoms such as nausea, vomiting, abdominal pain, 
and diarrhea 
Moderate Signs of pneumonia including fever, cough, and crepitations. No increased work of 
breathing. No manifestations related to severe disease 
Severe  Respiratory distress—respiratory rate ≥70 breaths/min for infants, ≥50breaths/min for 
children>1year. Oxygen saturation<92%. Dehydration requiring intravenous fluid support. 
Critical Acute respiratory distress syndrome (ARDS) or respiratory failure requiring ventilator 
support. Signs of shock, encephalopathy, myocardial injury or heart failure, coagulation 




Table 2. The severity of the chemotherapeutic regimen is classified based on the degree of myelosuppression1 8 
 9 
 10 
Mild Maintenance therapy in leukemia or targeted therapy 
Moderate  Interim maintenance therapy for ALL, solid tumor protocols 
Severe Induction, Consolidation, Delayed Intensification therapy for ALL, 
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Table 3. Demographics of hematological or oncological patients with positive COVID-19 reports, N=12 14 
 15 
 16 
Demography  N(%) 
Gender   
Male  9(75) 
Female  3(25) 
Age   
<5years   3(25) 
5-10years  1(8.3) 
11-14years  8(66.7) 
Disease type   
Oncology  9(75) 
Acute Lymphoblastic Leukemia (ALL)  3*(25) 
Acute Myeloid Leukemia  (AML)  1(8.3) 
Embryonal Rhabdomyosarcoma  1(8.3) 
Hepatoblastoma  1(8.3) 
Osteosarcoma  1(8.3) 
Chronic Myeloid Leukemia (CML)  1(8.3) 
Langerhans Cell Histiocytosis (LCH)  1(8.3) 
Hematology  3(25) 




Table 4. Clinical features, treatment and outcome of hematological or oncological patients with positive 21 




Clinical features  
Fever 10(83.3) 
Cough 7(58.3) 




Oxygen support 5(41.7) 
Antibiotics use 9(75) 
Outcome  
Mechanical ventilation 1(8.3) 
Inotrope support 1(8.3) 





Table 5. Association of COVID-19 status with delay in chemotherapy/local therapy among hematology and 28 
oncology patients, N=27 29 
 30 
 31 
COVID-19 Delay in Chemotherapy Total 2 p value 
Yes No 
Positive 8 1 9 12.963 
 
<0.01* 
 Negative 3 15 18 
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 34 





In this study, most children, 6(50%) with 
malignancies had a mild or asymptomatic 
infection, which is similar to the findings of 
other studies reviewing children with COVID-
19 and hematological or oncological 
diseases.7,9,10 The incidence of symptomatic 
infection 10(83.3%) in our cohort was also 
comparable to the incidence of symptomatic 
infection 26(72.2%) in children without 
underlying illness in a retrospective study from 
China.4 Retrospective review of 19 pediatric 
hematology-oncology patients from the USA 
reported that 84% of their children were 
symptomatic and 32% required respiratory 
support.7 One study from a cancer center in 
Chennai, India reported only 33% symptomatic 
infection in their cohort of 15 patients, and 7% 
required respiratory support while 5(41%) of 
our cohort required respiratory support.8 The 
study in Chennai was performed in the early 
days of the pandemic where all children with 
malignancies were screened irrespective of the 
symptoms, which likely explains the 
contrasting findings from our cohort.8 
The majority of our COVID-19 positive patients 
were hospitalized, 10(83.3%), which was in 
concordance with the retrospective study 
conducted in New York City where 55(75%) of 
COVID-19 patients required hospitalization.1 In 
contrast to our findings, only 5% of children 
with cancer required hospitalization for 
COVID-19 related symptoms in a study from 
New York City.11 Similarly, another study of six 
pediatric oncology patients from the USA 
showed mild infection in all their cohorts, none 
requiring hospitalization for COVID-19 or 
respiratory support.7 The higher incidence of 
hospitalization in our cohort is due to the 
departmental policy of admitting all febrile 
patients on active treatment for any 
oncological disease irrespective of their blood 
counts and clinical status.  
 
In our cohort, treatment was modified in the 
form of delaying chemotherapy or postponing 
surgery in more than half of the oncology 
patients who were positive for COVID-19.  The 
delay was significant in comparison to COVID-
19 negative patients. The majority of the delay 
in therapy was due to the physician’s decision 
to defer the planned therapy rather than due 
to COVID-related complications. A study 
conducted in New York City revealed a similar 
delay in providing cancer-related treatment to 
patients.9 The international consensus 
guidelines also advise to treat oncology 
patients as per clinical scenario with 
reasonable adaptations.12 A group of pediatric 
oncologists from China recommended to 
continue chemotherapy in pediatric oncology 
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unless they are suspected or confirmed to have 
COVID-19 and to avoid delay >7 d while 
children on maintenance therapy delays 
should be <14 d.13 The decision to delay critical 
cancer-directed therapy may adversely affect 
the long-term outcome in these children, thus 
pediatric oncologists face challenges regarding 
therapy. The findings in our study and other 
studies from USA and Italy indicate that in 
children without comorbidities except for 
cancer diagnosis, COVID-19 may not pose a 
significant threat in comparison to other viral 
illnesses, and in asymptomatic oncology 
patients whose therapy cannot be deferred, 
the myelosuppressive chemotherapy may be 
considered with close monitoring of 
patients.7,9 These results are fairly encouraging 
as most childhood cancers are aggressive 
requiring treatment and significant treatment 
delays can lead to disease progression 
eventually affecting the prognosis of the 
disease. 
 
Due to the ongoing pandemic, the problem 
was not only in providing treatment but also in 
performing complete risk stratification of 
patients. One patient with ALL had to be 
upgraded from intermediate to high-risk 
category as post-induction Minimal Residual 
Disease (MRD) remission could not be 
assessed. Various studies have been published 
regarding the impact of COVID-19 and delay in 
diagnosis as well as treatment due to COVID-
19 but few studies are depicting the effect of 
incomplete risk stratification due to 
unavailability of services in low- and middle-
income countries like Nepal.14,15 As the 
patient’s treatment had to be escalated, the 
long-term effects of toxic therapy remain 
unknown. The pediatric hematology-oncology 
services at PAHS despite being in the very early 
stages of operation could continue to provide 
regular services throughout the first and 
second wave of COVID-19 despite some 
obstacles in risk stratification and acquiring 
chemotherapy medications. A cross-sectional 
study conducted by St Jude Global Alliance and 
International Society for Pediatric Oncology, 
Memphis USA including 213 institutions in 79 
countries from all WHO regions to study the 
global effects of COVID-19 pandemic on 
pediatric cancer care reported complete 
closure of pediatric cancer care services 
(median 10 d, range 1-75 d) in 15(7%) 
centers.16 They found substantial disruption in 
cancer diagnosis and management particularly 
in low- and middle-income countries. Patan 
Hospital, being one of the treatment centers 
for suspected and confirmed cases of COVID-
19, played a vital role in continuing pediatric 
hematology and oncology services during the 
pandemic. 
 
One of the main limitations of our study is the 
sample size. As the pediatric hematology-
oncology services have been recently set up (2 
y) at Patan Hospital, PAHS, the number of 
children undergoing treatment is limited thus 
contributing to the small number of children in 
our study which might not depict the true 
picture in the community. Another limitation is 
the nonuniform Covid-19 testing policy of 
patients during the study period. At the 
beginning of the study, asymptomatic patients 
admitted for chemotherapy were tested with 
RT-PCR. During the study, the testing policy 
was revised as the pandemic situation changed 
so that asymptomatic patients requiring 
admission during the study were tested with 
antigen detection tests, and symptomatic 
patients with fever and /or respiratory and/or 
gastrointestinal symptoms requiring admission 
were tested with RT-PCR test. Our study is thus 
prone to potential selection bias, exaggerated 
by the small sample size and the changing 
policies on testing children during the study 
period. The third limitation of our study relates 
to the use of tests for the diagnosis of COVID-
19. We have used antigen detection test as the 
screening test in our study but the sensitivity 
of this test is limited.17 The study conducted in 
Nepal in rapid antigen test in asymptomatic 
population revealed sensitivity and specificity 
of 85% and 100% respectively with an accuracy 
of 93%.18 This is in contrast to the findings in 
various studies conducted in other countries 
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71%.17,19,20 There are also well-documented 
concerns regarding the sensitivity of RT-PCR 
for diagnosis of COVID-19.21 The study 
conducted in China revealed only 30-60% 
sensitivity for RT-PCR test done from 
oropharyngeal and nasopharyngeal secretions 
with the highest sensitivity (93%) from lower 
respiratory secretions.22 As we test 
oropharyngeal and nasopharyngeal secretions, 
we might have missed the cohort of children 
with cancer and COVID-19 who were not 
unwell enough to present to the hospital or 





Most of the pediatric hematology and 
oncology patients with COVID-19 recovered. 
There was a delay in the treatment of oncology 
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